Toll-like Receptor 4 Contributes to Vascular Remodelling and Endothelial Dysfunction in Angiotensin II-induced Hypertension
Overview
Authors
Affiliations
Background And Purpose: Toll-like receptor 4 (TLR4) signalling contributes to inflammatory cardiovascular diseases, but its role in hypertension and the associated vascular damage is not known. We investigated whether TLR4 activation contributed to angiotensin II (AngII)-induced hypertension and the associated vascular structural, mechanical and functional alterations.
Experimental Approach: AngII was infused (1.44 mg · kg(-1) · day(-1), s.c.) for 2 weeks in C57BL6 mice, treated with a neutralizing anti-TLR4 antibody or IgG (1 μg · day(-1); systolic BP (SBP) and aortic cytokine levels were measured. Structural, mechanical and contractile properties of aortic and mesenteric arterial segments were measured with myography and histology. RT-PCR and Western blotting were used to analyse these tissues and cultured vascular smooth muscle cells (VSMC) from hypertensive rats (SHR).
Key Results: Aortic TLR4 mRNA levels were raised by AngII infusion. Anti-TLR4 antibody treatment of AngII-treated mice normalised: (i) increased SBP and TNF-α, IL-6 and CCL2 levels; (ii) vascular structural and mechanical changes; (iii) altered aortic phenylephrine- and ACh-induced responses; (iv) increased NOX-1 mRNA levels, superoxide anion production and NAD(P)H oxidase activity and effects of catalase, apocynin, ML-171 and Mito-TEMPO on vascular responses; and (v) reduced NO release and effects of L-NAME on phenylephrine-induced contraction. In VSMC, the MyD88 inhibitor ST-2825 reduced AngII-induced NAD(P)H oxidase activity. The TLR4 inhibitor CLI-095 reduced AngII-induced increased phospho-JNK1/2 and p65 NF-κB subunit nuclear protein expression.
Conclusions And Implications: TLR4 up-regulation by AngII contributed to the inflammation, endothelial dysfunction, vascular remodelling and stiffness associated with hypertension by mechanisms involving oxidative stress. MyD88-dependent activation and JNK/NF-κB signalling pathways participated in these alterations.
Fang H, Cavdar O, Yao Z, Zhu X, Shen Y, Liu C J Hum Hypertens. 2025; 39(3):226-236.
PMID: 39789125 DOI: 10.1038/s41371-024-00982-7.
Zhou Q, Zhang Y, Shi W, Lu L, Wei J, Wang J Biomolecules. 2024; 14(11).
PMID: 39595632 PMC: 11591770. DOI: 10.3390/biom14111456.
Ecton K, Graham E, Risk B, Brown G, Stark G, Wei Y Front Microbiomes. 2024; 2.
PMID: 39323483 PMC: 11423633. DOI: 10.3389/frmbi.2023.1095997.
Florencio-Santiago O, Blas-Valdivia V, Serrano-Contreras J, Rojas-Franco P, Escalona-Cardoso G, Paniagua-Castro N Mar Drugs. 2024; 22(8).
PMID: 39195453 PMC: 11355432. DOI: 10.3390/md22080337.
Toll-like receptor 4 mutation mitigates gut microbiota-mediated hypertensive kidney injury.
Majumder S, Pushpakumar S, Almarshood H, Ouseph R, Gondim D, Jala V Pharmacol Res. 2024; 206:107303.
PMID: 39002869 PMC: 11287947. DOI: 10.1016/j.phrs.2024.107303.